2-(4-Iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing.
Journal of medical toxicology : official journal of the American College of Medical Toxicology March 1, 2014 Samuel J Stellpflug, Samantha E Kealey, Cullen B Hegarty et al. 92 citations
A new, highly potent designer drug called 25I-NBOMe, part of the 2C family, caused an isolated brief seizure, rapid heart rate, high blood pressure, agitation, and confusion in an 18-year-old woman who used it. She recovered with intravenous fluids and benzodiazepines and was discharged seven hours after ingestion. Standard drug tests often miss these substances. Urine analysis using advanced techniques found 25I-NBOMe at 7.5 ng/mL and also detected 25H-NBOMe, a related compound. Further testing identified excreted metabolites, aiding future detection. This case highlights the dangers of evolving synthetic drugs and the need for specialized laboratory methods to confirm exposure.